BR112014006910A2 - composto, substância farmacêutica do composto, método para produzir a substância farmacêutica, uso da substância farmacêutica, método de ensaio de titulação, e, composição farmacêutica e parafarmacêutica - Google Patents

composto, substância farmacêutica do composto, método para produzir a substância farmacêutica, uso da substância farmacêutica, método de ensaio de titulação, e, composição farmacêutica e parafarmacêutica

Info

Publication number
BR112014006910A2
BR112014006910A2 BR112014006910A BR112014006910A BR112014006910A2 BR 112014006910 A2 BR112014006910 A2 BR 112014006910A2 BR 112014006910 A BR112014006910 A BR 112014006910A BR 112014006910 A BR112014006910 A BR 112014006910A BR 112014006910 A2 BR112014006910 A2 BR 112014006910A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical
compound
substance
pharmaceutical substance
para
Prior art date
Application number
BR112014006910A
Other languages
English (en)
Inventor
Vitalyevich Akhapkin Roman
Ivanovna Akhapkina Valentina
Original Assignee
Vitalyevich Akhapkin Roman
Ivanovna Akhapkina Valentina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47914659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014006910(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vitalyevich Akhapkin Roman, Ivanovna Akhapkina Valentina filed Critical Vitalyevich Akhapkin Roman
Publication of BR112014006910A2 publication Critical patent/BR112014006910A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N31/00—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods
    • G01N31/16—Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroup; Apparatus specially adapted for such methods using titration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/16—Separation or purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/18—Stabilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
BR112014006910A 2011-09-22 2012-09-20 composto, substância farmacêutica do composto, método para produzir a substância farmacêutica, uso da substância farmacêutica, método de ensaio de titulação, e, composição farmacêutica e parafarmacêutica BR112014006910A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2011138840/15A RU2480214C1 (ru) 2011-09-22 2011-09-22 Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов
PCT/RU2012/000773 WO2013043085A1 (ru) 2011-09-22 2012-09-20 Фармацевтическая субстанция (варианты) и полученные на ее основе композиции, обладающие модуляторной активностью с соразмерным влиянием

Publications (1)

Publication Number Publication Date
BR112014006910A2 true BR112014006910A2 (pt) 2017-04-11

Family

ID=47914659

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014006910A BR112014006910A2 (pt) 2011-09-22 2012-09-20 composto, substância farmacêutica do composto, método para produzir a substância farmacêutica, uso da substância farmacêutica, método de ensaio de titulação, e, composição farmacêutica e parafarmacêutica

Country Status (12)

Country Link
US (1) US20140315972A1 (pt)
EP (1) EP2762138A4 (pt)
JP (1) JP2014526551A (pt)
CN (1) CN103987386A (pt)
BR (1) BR112014006910A2 (pt)
CA (1) CA2849711A1 (pt)
EA (1) EA201490615A1 (pt)
MD (1) MD20140042A2 (pt)
MX (1) MX2014003483A (pt)
RU (1) RU2480214C1 (pt)
UA (1) UA111981C2 (pt)
WO (1) WO2013043085A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2524651C1 (ru) * 2013-06-20 2014-07-27 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме раствора для инъекций и способ ее получения
LV15003B (lv) * 2013-10-22 2015-08-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
RU2539375C1 (ru) * 2013-11-07 2015-01-20 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция в форме таблетки и способ ее получения
EP2891491A1 (en) * 2014-01-03 2015-07-08 Merz Pharma GmbH & Co. KGaA Use of (r)-phenylpiracetam for the treatment of sleep disorders
EP3127539A1 (en) * 2015-08-03 2017-02-08 Latvian Institute Of Organic Synthesis Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures
RU2748419C2 (ru) * 2017-02-20 2021-05-25 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Производные 4-фенилпирролидона, обладающие противосудорожной и ноотропной активностью, как средства лечения эпилепсии и пароксизмальных состояний
RU2696277C2 (ru) * 2017-08-15 2019-08-01 Общество С Ограниченной Ответственностью "Валента - Интеллект" Новый состав N-карбамоилметил-4-фенил-2-пирролидона
LV15614A (lv) * 2020-07-30 2022-02-20 Latvijas Organiskās Sintēzes Institūts 2-(2-okso-3-pirolin-1-il)acetamīdi kā pretkrampju līdzekļi

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU797219A1 (ru) * 1979-05-08 1995-07-25 Ленинградский государственный педагогический институт им.А.И.Герцена N-карбамоилметил-4-фенил-2-пирролидон, обладающий гипотензивной активностью
SU1265192A1 (ru) * 1984-06-27 1986-10-23 2-Ой Московский Ордена Ленина Государственный Медицинский Институт Им.Н.И.Пирогова Способ получени амидов 4-фенил-пирролидон-2-уксусной-1 кислоты
EP0363489A4 (en) * 1988-04-18 1991-09-11 Mo Med Inst Pirogova Method for obtaining 4-phenyl-2-pyrrolidone-acetic-1 acid amide
RU2050851C1 (ru) 1990-08-28 1995-12-27 Институт медико-биологических проблем Вещество, проявляющее ноотропную активность
EA002380B1 (ru) * 1999-07-21 2002-04-25 Российский Государственный Педагогический Университет Им. А.И.Герцена Антиишемическое средство
US6423739B1 (en) * 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
RU2183117C1 (ru) * 2000-11-03 2002-06-10 Закрытое акционерное общество "АСГЛ-Исследовательские Лаборатории" Средство для нормализации артериального давления и способ лечения гипертонической болезни
RU2192858C1 (ru) * 2001-05-16 2002-11-20 Закрытое акционерное общество "АСГЛ-Исследовательские Лаборатории" Средство, обладающее антиишемической, гипотензивной и антигипоксической активностью
RU2232578C1 (ru) * 2003-04-10 2004-07-20 Ахапкина Валентина Ивановна Вещество, обладающее антидепрессивной активностью
RU2240783C1 (ru) * 2003-07-17 2004-11-27 Открытое акционерное общество "Щелковский витаминный завод" Фармацевтическая композиция, обладающая ноотропной активностью, и способ ее получения
RU2289404C1 (ru) * 2005-04-06 2006-12-20 ГОУ ВПО "Московский государственный медико-стоматологический университет Министерства здравоохранения РФ" Способ премедикации у пациентов со средним уровнем психоэмоционального напряжения при амбулаторных стоматологических вмешательствах
LV13630B (en) 2006-03-16 2007-12-20 Olainfarm As Method of preparation and use of pharmaceutically active n-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone
CN101405936A (zh) * 2006-03-24 2009-04-08 松下北美公司美国分部松下汽车系统公司 具有父母最大音量控制的音频系统
RU2329804C2 (ru) * 2006-03-28 2008-07-27 Валентина Ивановна Ахапкина Вещество, обладающее нейротропной - нейромодуляторной активностью
WO2008012268A1 (en) * 2006-07-25 2008-01-31 Zach System S.P.A. Process for the preparation of levetiracetam
RU2327458C1 (ru) * 2007-02-19 2008-06-27 Открытое акционерное общество "Щелковский витаминный завод" Новая препаративная форма вещества, обладающего ноотропной и нейромодуляторной активностью, и способ ее получения
RU2423969C2 (ru) * 2007-10-12 2011-07-20 Старрайд Фармасьютикал Лимитед Способ микронизации n-карбамоил-метил-4-фенил-2-пирролидона и лекарственный препарат, содержащий вододиспергируемую органическую лекарственную субстанцию в виде микронизированного порошка n-карбамоил-метил-4-фенил-2-пирролидона
RU2391976C2 (ru) * 2007-10-18 2010-06-20 Открытое Акционерное Общество "Валента Фармацевтика" Фармацевтический состав в виде микроинкапсулированных поликомпонентных частиц из n-карбамоил-метил-4-фенил-2-пирролидона и вспомогательного нейтрального органического низкомолекулярного компонента и способ его микрокапсулирования
US20090176740A1 (en) * 2007-11-30 2009-07-09 Phillips Ii Dauglas James Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
CN104491864A (zh) 2008-04-21 2015-04-08 奥德纳米有限公司 用于治疗耳部疾病和病况的耳用调配物及方法
JP2010024156A (ja) * 2008-07-16 2010-02-04 Ucb Pharma Sa レベチラセタムを含む医薬組成物
MX2011001384A (es) * 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
RU2392915C1 (ru) * 2009-04-14 2010-06-27 Федеральное государственное учреждение "Новокузнецкий научно-практический центр медико-социальной экспертизы и реабилитации инвалидов Федерального агентства по здравоохранению и социальному развитию" (ФГУ ННПЦ МСЭ и РИ Росздрава) Способ формирования двигательных функций у инвалидов с позвоночно-спинно-мозговой травмой
RU2414898C1 (ru) * 2009-09-18 2011-03-27 Открытое Акционерное Общество "Валента Фармацевтика" Фармацевтическая композиция в форме раствора для инъекций, обладающая ноотропной активностью, и способ ее получения
ES2664727T3 (es) * 2009-10-22 2018-04-23 University College Dublin National University Of Ireland, Dublin Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP
RU2418588C1 (ru) * 2009-12-28 2011-05-20 Учреждение Российской Академии Медицинских Наук Научно-Исследовательский Институт Психического Здоровья Сибирского Отделения Рамн Способ лечения эндометриоза у женщин с тревожно-депрессивными расстройствами

Also Published As

Publication number Publication date
EP2762138A1 (en) 2014-08-06
WO2013043085A8 (ru) 2013-10-31
RU2011138840A (ru) 2013-03-27
RU2480214C1 (ru) 2013-04-27
WO2013043085A1 (ru) 2013-03-28
CN103987386A (zh) 2014-08-13
MD20140042A2 (ro) 2014-09-30
CA2849711A1 (en) 2013-03-28
JP2014526551A (ja) 2014-10-06
EA201490615A1 (ru) 2014-06-30
EP2762138A4 (en) 2015-12-02
MX2014003483A (es) 2014-11-10
UA111981C2 (uk) 2016-07-11
US20140315972A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BR112014001346A2 (pt) composto nanotransportador, método, composto farmacêutico e uso de um composto
BR112014006910A2 (pt) composto, substância farmacêutica do composto, método para produzir a substância farmacêutica, uso da substância farmacêutica, método de ensaio de titulação, e, composição farmacêutica e parafarmacêutica
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BR112015006824A2 (pt) anticorpo igg biespecífico, método para produzir um anticorpo igg biespecífico, anticorpo, composição farmacêutica e uso de um anticorpo igg biespecífico
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
BR112013020611A2 (pt) método para produção de compostos quelato de aminoácido, compostos quelato de aminoácido e uso de compostos quelato de aminoácido
BR112013020362A2 (pt) processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
BR112013023653A2 (pt) anticorpo biespecífico, método de preparação do anticorpo, e composição farmacêutica
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112014008126A2 (pt) composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção
BR112015002091A2 (pt) método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014007134A2 (pt) usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto
BR112013028959A2 (pt) composto, processo para o preparo de um composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI0922174A2 (pt) preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica
BR112014015046A2 (pt) dispersão de microcápsula, método para produzir uma dispersão de microcápsula, microcápsula, e, uso de uma dispersão de microcápsulas
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
CO6940429A2 (es) Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparación
BR112014013177A2 (pt) composto, composição farmacêutica e uso de um composto
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements